To address potential pVHL restoration strategies, the use of PROTACs that utilize VHL as an E3 ligase has proven to be a promising tool for cancer treatment; however, one of the main limitations is that they are large and highly polar molecules, and their bioavailability is low, which complicates oral administration and proper tissue and cell distribution. Here, VHL is linked to cancer.